Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Net Cash Flow (2022 - 2025)

Corvus Pharmaceuticals has reported Net Cash Flow over the past 4 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $1.7 million for Q4 2025, down 57.91% from a year ago — trailing twelve months through Dec 2025 was -$4.2 million (up 87.84% YoY), and the annual figure for FY2025 was -$4.2 million, down 7.32%.
  • Net Cash Flow for Q4 2025 was $1.7 million at Corvus Pharmaceuticals, up from -$11.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for CRVS hit a ceiling of $12.4 million in Q3 2023 and a floor of -$32.0 million in Q1 2022.
  • Median Net Cash Flow over the past 4 years was -$3.8 million (2022), compared with a mean of -$5.6 million.
  • Biggest five-year swings in Net Cash Flow: surged 420.06% in 2023 and later tumbled 1051.55% in 2024.
  • Corvus Pharmaceuticals' Net Cash Flow stood at -$11.4 million in 2022, then surged by 34.51% to -$7.5 million in 2023, then surged by 154.24% to $4.1 million in 2024, then crashed by 57.91% to $1.7 million in 2025.
  • The last three reported values for Net Cash Flow were $1.7 million (Q4 2025), -$11.8 million (Q3 2025), and $9.7 million (Q2 2025) per Business Quant data.